Inhibitory effects of lupane‑type triterpenoid saponins from the leaves of Acanthopanax gracilistylus on lipopolysaccharide-induced TNF‑α, IL‑1β and high‑mobility group box 1 release in macrophages

Zou,Qin‑Peng; Liu,Xiang‑Qian; Huang,Jian‑Jun; Yook,Chang‑Soo; Whang,Wan‑Kyunn; Lee,Hyeong‑Kyu; Kwon,Ok‑Kyoung

doi:10.3892/mmr.2017.7767

Inhibitory effects of lupane‑type triterpenoid saponins from the leaves of Acanthopanax gracilistylus on lipopolysaccharide-induced TNF‑α, IL‑1β and high‑mobility group box 1 release in macrophages

Authors:
- Qin‑Peng Zou
- Xiang‑Qian Liu
- Jian‑Jun Huang
- Chang‑Soo Yook
- Wan‑Kyunn Whang
- Hyeong‑Kyu Lee
- Ok‑Kyoung Kwon
View Affiliations

Affiliations: Changsha Broad‑Ocean Bio‑Science and Technique Co., Ltd., Changsha, Hunan 410205, P.R. China, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan 410208, P.R. China, Department of Clinical Biochemistry, Xiangya Medical College, Central South University, Changsha, Hunan 410013, P.R. China, College of Pharmacy, Kyung Hee University, Seoul 130‑701, Republic of Korea, College of Pharmacy, Chung‑Ang University, Seoul 156‑756, Republic of Korea, Korea Research Institute of Bioscience and Biotechnology, Daejeon 341‑41, Republic of Korea
Published online on: October 11, 2017 https://doi.org/10.3892/mmr.2017.7767
Pages: 9149-9156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acanthopanax gracilistylus (AGS) has long been used in traditional Chinese medicine for the treatment of various inflammatory diseases. 3‑O‑β‑D‑glucopyranosyl 3α, 11α‑dihydroxylup‑20(29)‑en‑28‑oic acid, acantrifoside A, acankoreoside D, acankoreoside B and acankoreoside A are major lupane‑type triterpenoid saponins derived from AGS. In the present study, these five saponins were isolated from AGS by chromatography and their anti‑inflammatory activities were investigated in lipopolysaccharide (LPS)‑treated RAW264.7 macrophages. Cell viability was evaluated by MTT assay. Tumor necrosis factor (TNF)‑α, interleukin (IL)‑1β and NF‑κB p65 were measured by ELISA. The gene expression levels of TNF‑α and IL‑1β was detected by reverse‑transcription polymerase chain reaction. And high‑mobility group box 1 (HMGB1) were analyzed by western blotting. The results demonstrated that these five saponins signiﬁcantly suppressed LPS‑induced expression of TNF‑α and IL‑1β at the mRNA and protein level in RAW264.7 cells. Further analysis revealed that acankoreoside A and acankoreoside B were able to reduce the secretion of HMGB1 and NF‑κB activity induced by LPS in RAW264.7 macrophages. Taken together, these results suggested that the anti‑inflammatory activity of AGS‑derived saponins may be associated with the downregulation of TNF‑α and IL‑1β, and the ‘late‑phase’ proinflammatory cytokine HMGB1, via negative regulation of the NF‑κB pathway in RAW264.7 cells.

View Figures

View References

1	Morson BC: Pathology of inflammatory disease. Proc R Soc Med. (63 Suppl): pp. S631970;
2	Gholijani N, Gharagozloo M, Farjadian S and Amirghofran Z: Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophages. J Immunotoxicol. 13:157–164. 2016. View Article : Google Scholar : PubMed/NCBI
3	Akira S, Hirano T, Taga T and Kishimoto T: Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 4:2860–2867. 1990.PubMed/NCBI
4	Beutler B and Cerami A: Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 320:584–588. 1986. View Article : Google Scholar : PubMed/NCBI
5	Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–251. 1999. View Article : Google Scholar : PubMed/NCBI
6	Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 19:5237–5246. 1999. View Article : Google Scholar : PubMed/NCBI
7	Abraham E, Arcaroli J, Carmody A, Wang H and Tracey KJ: HMG-1 as a mediator of acute lung inflammation. J Immunol. 165:2950–2954. 2000. View Article : Google Scholar : PubMed/NCBI
8	Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
9	Lotze MT and Tracey KJ: High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar : PubMed/NCBI
10	Andersson U and Tracey KJ: HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 29:139–162. 2011. View Article : Google Scholar : PubMed/NCBI
11	Harris HE and Raucci A: Alarmin (g) news about danger: Workshop on innate danger signals and HMGB1. EMBO Rep. 7:774–778. 2006.PubMed/NCBI
12	Bianchi ME: DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol. 81:1–5. 2007. View Article : Google Scholar : PubMed/NCBI
13	Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H and Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 192:565–570. 2000. View Article : Google Scholar : PubMed/NCBI
14	Sha Y, Zmijewski J, Xu Z and Abraham E: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol. 180:2531–2537. 2008. View Article : Google Scholar : PubMed/NCBI
15	Li X, Wang LK, Wang LW, Han XQ, Yang F and Gong ZJ: Cisplatin protects against acute liver failure by inhibiting nuclear HMGB1 release. Int J Mol Sci. 14:11224–11237. 2013. View Article : Google Scholar : PubMed/NCBI
16	Chang Y, Huang X, Liu Z, Han G, Huang L, Xiong YC and Wang Z: Dexmedetomidine inhibits the secretion of high mobility group box 1 from lipopolysaccharide-activated macrophages in vitro. J Surg Res. 181:308–314. 2013. View Article : Google Scholar : PubMed/NCBI
17	Shan BE, Yoshita Y, Sugiur T and Yamashita U: Suppressive effect of Chinese medicinal herb, Acanthopanax gracilistylus, extract on human lymphocytes in vitro. Clin Exp Immunol. 118:41–48. 1999. View Article : Google Scholar : PubMed/NCBI
18	China Pharmacopoeia Commission: Pharmacopoeia of People's Republic of China. 1. Chinese Medical Science and Technology Press; Beijing: pp. 612010
19	Cai XF, Lee IS, Shen G, Dat NT, Lee JJ and Kim YH: Triterpenoids from Acanthopanax koreanum root and their inhibitory activities on NFAT transcription. Arch Pharm Res. 27:825–828. 2004. View Article : Google Scholar : PubMed/NCBI
20	Park SH, Nhiem NX, Kiem PV, Choi EM, Kim JA and Kim YH: A new norlupane triterpene from the leaves of Acanthopanax koreanum increases the differentiation of osteoblastic MC3T3-e1 cells. Arch Pharm Res. 33:75–80. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wu YL, Jiang YZ, Jin XJ, Lian LH, Piao JY, Wan Y, Jin HR, Lee J Joon and Nan JX: Acanthoic acid, a diterpene in Acanthopanax koreanum, protects acetaminophen-induced hepatic toxicity in mice. Phytomedicine. 17:475–479. 2010. View Article : Google Scholar : PubMed/NCBI
22	Nhiem NX, Kiem PV, Minh CV, Tai BH, Tung NH, Ha do T, Soung KS, Kim JH, Ahn JY, Lee YM and Kim YH: Structure-activity relationship of lupane-triterpene glycosides from Acanthopanax koreanum on spleen lymphocyte IL-2 and IFN-gamma. Bioorg Med Chem Lett. 20:4927–4931. 2010. View Article : Google Scholar : PubMed/NCBI
23	Huang WC, Li Z, Li XJ, Gong LM, Liu XQ, Kwon OK, Ye HX and Lee HK: Chemical composition, anti-inflammatory activity and cytotoxic activity of the liposoluble constituents from different parts of Acanthopanax evodiaefolius by the Herbal Blitzkrieg Extractor. Environ Toxicol Pharmacol. 38:406–411. 2014. View Article : Google Scholar : PubMed/NCBI
24	Yook CS, Liu XQ, Chang SY, Park SY and Nohara T: Lupane triterpene glycosides from the leaves of Acanthopanax gracilistylus. Chem Pharm Bull (Tokyo). 50:1383–1385. 2002. View Article : Google Scholar : PubMed/NCBI
25	Liu XQ, Yook CS and Chang SY: Chemical constituents of Acanthopanax gracilistylus. Chin Tradit Herb Drugs. 35:250–252. 2004.(In Chinese).
26	Liu XQ, Chang SY, Park SY, Nohara T and Yook CS: A new lupane triterpene glycosides from the leaves of Acanthopanax gracilistylus. Arch Pharm Res. 25:831–836. 2002. View Article : Google Scholar : PubMed/NCBI
27	Zou QP, Liu XQ, Lee HK and Oh OJ: Lupane- triterpenoids from the methanol extracts of leaves of Acanthopanax gracilistylus W.W. Smith. J Lanzhou Univ (Natural Sciences). 47:120–126. 2011.
28	Ulloa L and Messmer D: High-mobility group box 1 (HMGB1) protein: Friend and foe. Cytokine Growth Factor Rev. 17:189–201. 2006. View Article : Google Scholar : PubMed/NCBI
29	Otterlei M, Ostgaard K, Skjåk-Braek G, Smidsrød O, Soon-Shiong P and Espevik T: Induction of cytokine production from human monocytes stimulated with alginate. J Immunother (1991). 10:286–291. 1991. View Article : Google Scholar : PubMed/NCBI
30	Fiedler VB, Loof I, Sander E, Voehringer V, Galanos C and Fournel MA: Monoclonal antibody to tumor necrosis factore alpha prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med. 120:574–588. 1992.PubMed/NCBI
31	Van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJ, Eerenberg AJ, de Groot ER, Jansen J, Gallati H, Büller HR, et al: Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 179:1253–1259. 1994. View Article : Google Scholar : PubMed/NCBI
32	Van der Poll T, Levi M, van Deventer SJ, ten Cate H, Haagmans BL, Biemond BJ, Büller HR, Hack CE and ten Cate JW: Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 83:446–451. 1994.PubMed/NCBI
33	Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, et al: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA. 271:1836–1843. 1994. View Article : Google Scholar : PubMed/NCBI
34	Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, et al: Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet. 351:929–933. 1998. View Article : Google Scholar : PubMed/NCBI
35	Gao H, Wu L, Kuroyanagi M, Harada K, Kawahara N, Nakane T, Umehara K, Hirasawa A and Nakamura Y: Antitumor-promoting constituents from Chaenomeles sinensis KOEHNE and their activities in JB6 mouse epidermal cells. Chem Pharm Bull (Tokyo). 51:1318–1321. 2003. View Article : Google Scholar : PubMed/NCBI
36	Fogo AS, Antonioli E, Calixto JB and Campos AH: Tormentic acid reduces vascular smooth muscle cell proliferation and survival. Eur J Pharmacol. 615:50–54. 2009. View Article : Google Scholar : PubMed/NCBI